Innovation

Molecular Container to Enhance Aqueous Solubility of Drugs

University of Maryland
posted on 08/18/2010

Researchers at the University of Maryland have discovered a new cucurbit[n]uril-type molecular container that binds to a variety of FDA approved agents in water. For example the new CB[n]-type container binds to Rocuronium which is a widely used anesthetic during surgery. By sequestering Rocuronium post-operatively by the application of the new CB[n]-type container, the recovery time of the patient is decreased.

Suggested Uses

- Reversal agent for rocuronium following surgery
- Solubility Enhancement for a variety of pharmaceutical agents and drugs

Advantages

- Highly water soluble
- Containers can be produced in scalable quantities at minimal cost
- Promising results from toxicity tests on human cell lines

Innovation Details
 

Detailed Description

One of the key obstacles encountered by the pharmaceutical industry is the deficient bioavailability of drugs due to poor aqueous solubility. One approach to address this problem is the development of molecular containers that encapsulate and thereby solubilize otherwise insoluble drugs in an aqueous environment. Ideally, such molecular container-drug complexes can be delivered in a targeted manner in the human body. Accordingly, water soluble molecular containers are highly desirable toward the formulation of a wide array of pharmaceutical drugs and agents. Currently, the most commonly used class of water soluble molecular containers for drug delivery applications are the cyclodextrins. Cyclodextrins however, have their drawbacks and cannot be considered as a universal container for all possible drugs. Therefore a great need exists for the invention of new classes of molecular containers that will provide an alternative to cyclodextrins as solubility enhancers and delivery agents.

Researchers at the University of Maryland have discovered a new cucurbit[n]uril-type molecular container that binds to a variety of FDA approved agents in water. For example the new CB[n]-type container binds to Rocuronium which is a widely used anesthetic during surgery. By sequestering Rocuronium post-operatively by the application of the new CB[n]-type container, the recovery time of the patient is decreased. The excellent aqueous solubility (≥ 100 mM) of this new CB[n]-type container makes it ideal for intravenous administration. The new CB[n]-type container has also been successfully tested for enhancing the aqueous solubility of a multitude of FDA approved pharmaceuticals including anti-cancer, anti-arrhythmic, anti-clotting and anti-histamine drugs and agents. Toxicity studies in human cell lines establish that the new CB[n]-type container is bio-compatible (e.g. non-toxic). A scalable, efficient, and cost effective synthetic route to this compound has also been developed by the same researchers.

File Number: LS-2010-039 

Web site: http://otc.umd.edu


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at University of Maryland for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


Followed By

Follow this innovation

Icon_avatar

vpajak

Member since
Aug 2010

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

8,815 members 16,688 innovations 159 organizations

Browse

Patrick Jones, Ph.D. Director, Technology Transfer - University of Arizona

"The iBridge Network nicely embodies the ideals of a well-designed, non-profit mechanism for aggregating, searching, and disseminating innovations from multiple research institutions."  read more...